A Study to Test the Effectiveness of the Herbal Medicine Puricyn 30™ Used Along with Standard Treatment in People with Type 2 Diabetes.

Effectiveness of Advanced Supercritical Fluid Extraction based herbal drug (Puricyn 30TM) as an adjunctive therapy in the management of Type 2 Diabetic Patients: A Randomized Controlled, Double-Blind Clinical Trial. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096098

Enrollment

Registered

2025-10-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients receiving antihyperglycemic medication before randomization and HbA1c between 6.5% to 10% at randomization. Patients willing to give informed consent.

Exclusion criteria

Exclusion criteria: Type 1 Diabetes or uncontrolled T2DM with HbA1c more than 10 %. Patients with known hypersensitivity to any herbal component Pregnant or lactating women Patients with history of severe liver or kidney disease.

Design outcomes

Primary

Measure	Time frame
Puricyn 30 a SCFE-based novel herbal formulation may provide improvement in insulin sensitivity. Timepoint: Puricyn 30 a SCFE-based novel herbal formulation may provide improvement in insulin sensitivity after 90 days of treatment.	—

Secondary

Measure	Time frame
Puricyn 30 a SCFE-based novel herbal formulation may help in reduction of HbA1c, FBS, PPBS levels. Timepoint: 90 days	—

Countries

India

Contacts

Public ContactDr V Chitra

Purple life sciences pvt.ltd

srivarathan@gmail.com09884935025

Outcome results